Edition:
India

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

99.37USD
20 Sep 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$99.37
Open
--
Day's High
--
Day's Low
--
Volume
500
Avg. Vol
1,292,271
52-wk High
$99.65
52-wk Low
$58.61

Latest Key Developments (Source: Significant Developments)

Celgene's Cc-486 Tested As Maintenance Therapy For AML Succeeds In Phase 3 Study
Friday, 13 Sep 2019 

Sept 12 (Reuters) - Celgene Corp ::CELGENE ANNOUNCES PHASE 3 QUAZAR® AML-001 STUDY OF CC-486 AS MAINTENANCE THERAPY IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA MET PRIMARY AND KEY SECONDARY ENDPOINTS.CELGENE CORP - TOP-LINE ANALYSIS SHOWED A HIGHLY STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL FOR CC-486.CELGENE CORP - CELGENE PLANS REGULATORY SUBMISSIONS BEGINNING IN 1H 2020.CELGENE CORP - CC-486 WAS WELL-TOLERATED AND THERE WERE NO UNEXPECTED SAFETY EVENTS IN QUAZAR AML-001.CELGENE CORP - KEY SECONDARY ENDPOINT OF RELAPSE-FREE SURVIVAL (RFS) ALSO SHOWED A STATISTICALLY SIGNIFICANT IMPROVEMENT..CELGENE CORP - DATA FROM QUAZAR AML-001 WILL BE SUBMITTED TO A FUTURE MEDICAL MEETING..  Full Article

Celgene Reports Second Quarter 2019 Operating And Financial Results
Tuesday, 30 Jul 2019 

July 30 (Reuters) - Celgene Corp ::CELGENE REPORTS SECOND QUARTER 2019 OPERATING AND FINANCIAL RESULTS.Q2 REVENUE $4.4 BILLION VERSUS REFINITIV IBES ESTIMATE OF $4.23 BILLION.Q2 EARNINGS PER SHARE $2.16.SEES FY 2020 REVENUE $19 BILLION TO $20 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $2.63 -- REFINITIV IBES DATA.COMPANY RAISES 2019 TOTAL REVENUE GUIDANCE; REAFFIRMS 2020 OUTLOOK.SEES FY TOTAL REVENUE $17.2 BILLION - $17.4BLN.FULL-YEAR 2019 TOTAL REVENUE INCREASE DRIVEN BY POMALYST(®) AND ABRAXANE(®) PERFORMANCE.REVLIMID SALES FOR Q2 WERE $2,732 MILLION, AN INCREASE OF 11 PERCENT YEAR-OVER-YEAR.SEES FY 2019 GAAP DILUTED EPS $8.71 - $9.44.SEES FY 2019 ADJUSTED DILUTED EPS $10.65 - $10.85.FY2019 EARNINGS PER SHARE VIEW $10.73, REVENUE VIEW $17.11 BILLION -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED DILUTED EPS $10.65 - $10.85.  Full Article

Celgene Says FDA Approves Otezla (Apremilast) For Treatment Of Oral Ulcers Associated With Behçet’s Disease
Friday, 19 Jul 2019 

July 19 (Reuters) - Celgene Corp ::FDA APPROVES OTEZLA® (APREMILAST) FOR THE TREATMENT OF ORAL ULCERS ASSOCIATED WITH BEHÇET’S DISEASE.CELGENE CORP - FDA APPROVAL WAS BASED ON EFFICACY AND SAFETY RESULTS FROM RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 3 RELIEF STUDY.CELGENE CORP - U.S. FDA APPROVED OTEZLA 30 MG TWICE DAILY (BID) FOR TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHÇET'S DISEASE.CELGENE - SEES REGULATORY DECISION FOR OTEZLA IN ORAL ULCERS ASSOCIATED WITH BEHÇET'S DISEASE FROM PHARMACEUTICALS & MEDICAL DEVICES AGENCY IN JAPAN IN H2 2019.  Full Article

BeiGene Regains Global Rights to Investigational Anti-PD-1 Antibody Tislelizumab
Monday, 17 Jun 2019 

June 17 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE REGAINS FULL GLOBAL RIGHTS TO ITS INVESTIGATIONAL ANTI-PD-1 ANTIBODY TISLELIZUMAB.BEIGENE LTD - ENTERED INTO A MUTUAL AGREEMENT WITH CELGENE CORPORATION TO TERMINATE PARTIES' GLOBAL COLLABORATION FOR TISLELIZUMAB.BEIGENE LTD - IN CONNECTION WITH TERMINATION, CELGENE HAS AGREED TO PAY $150 MILLION TO BEIGENE.BEIGENE LTD - BEIGENE EXPECTS TISLELIZUMAB TO RECEIVE ITS FIRST REGULATORY APPROVAL LATER THIS YEAR..  Full Article

Celgene And Acceleron Announce FDA Acceptance Of Biologics License Application For Luspatercept
Tuesday, 4 Jun 2019 

June 4 (Reuters) - Celgene Corp ::CELGENE CORPORATION AND ACCELERON PHARMA ANNOUNCE U.S. FDA ACCEPTS LUSPATERCEPT BIOLOGICS LICENSE APPLICATION IN MYELODYSPLASTIC SYNDROMES AND BETA-THALASSEMIA.  Full Article

Celgene Presents Data From A Phase 1/2 Clinical Study Of Iberdomide In Combination With Dexamethasone
Sunday, 2 Jun 2019 

June 2 (Reuters) - Celgene Corp ::CELGENE PRESENTS DATA FROM A PHASE 1/2 CLINICAL STUDY OF IBERDOMIDE IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA AT ASCO 2019.CELGENE C- INVESTIGATIONAL TREATMENT DEMONSTRATES FAVORABLE EARLY SAFETY AND EFFICACY DATA IN PATIENTS WHO HAD RECEIVED A MEDIAN FIVE PRIOR TREATMENTS.CELGENE - OVERALL RESPONSE RATE WAS 32%, WITH 29% ACHIEVING A PARTIAL RESPONSE AND TWO PATIENTS ACHIEVING A VERY GOOD PARTIAL RESPONSE.SIX PATIENTS (9%) DISCONTINUED TREATMENT DUE TO ADVERSE EVENTS.  Full Article

Bristol-Myers Squibb Co Announces Extension Of The Expiration Date For Exchange Offers For Celgene Corp Notes
Friday, 24 May 2019 

May 24 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES EXTENSION OF THE EXPIRATION DATE FOR EXCHANGE OFFERS FOR CELGENE CORPORATION NOTES.BRISTOL-MYERS SQUIBB - EXTENDS EXPIRATION DATE FROM 5:00 P.M., NEW YORK CITY TIME, ON JUNE 3, 2019, TO 5:00 P.M., NEW YORK CITY TIME, ON JULY 8, 2019.BRISTOL-MYERS SQUIBB - EXTENSION OF EXPIRATION DATE OF OFFERS TO EXCHANGE NOTES ISSUED BY CELGENE FOR UP TO $19.85 BILLION OF NEW NOTES TO BE ISSUED BY CO.  Full Article

Celgene Receives European Commission Approvals For Revlimid® (Lenalidomide) And Imnovid® (Pomalidomide)-Based Triplet Combination Regimens For Patients With Multiple Myeloma
Thursday, 16 May 2019 

Celgene Corp ::CELGENE RECEIVES EUROPEAN COMMISSION APPROVALS FOR REVLIMID® (LENALIDOMIDE) AND IMNOVID® (POMALIDOMIDE)-BASED TRIPLET COMBINATION REGIMENS FOR PATIENTS WITH MULTIPLE MYELOMA.CELGENE CORP - APPROVAL FOR REVLIMID TRIPLET (RVD) WAS SUPPORTED BY DATA FROM SWOG S0777(3).CELGENE CORP - EUROPEAN COMMISSION HAS APPROVED TWO OF CELGENE'S IMID(®)-BASED COMBINATION REGIMENS.CELGENE CORP - APPROVAL OF IMNOVID TRIPLET (PVD) WAS SUPPORTED BY DATA FROM OPTIMISMM(4).CELGENE CORP - EC APPROVED TWO NEW TRIPLET REGIMENS BASED ON CELGENE'S PROPRIETARY IMID TREATMENTS, REVLIMID (LENALIDOMIDE) AND IMNOVID (POMALIDOMIDE).  Full Article

Celgene Corp Announces Pomalyst Granted Breakthrough Therapy Designation From FDA For HIV-Positive And Negative Kaposi Sarcoma
Monday, 13 May 2019 

May 13 (Reuters) - Celgene Corp ::CELGENE CORPORATION ANNOUNCES POMALYST® GRANTED BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR HIV-POSITIVE AND NEGATIVE KAPOSI SARCOMA.CELGENE CORP - CELGENE PLANS TO SUBMIT SNDA BY END OF 2019.CELGENE CORP - CELGENE PLANS ADDITIONAL STUDIES WITH AIDS MALIGNANCY CONSORTIUM IN U.S. AND SUB-SAHARAN AFRICA.CELGENE CORP - POMALYST IS NOT APPROVED FOR KAPOSI SARCOMA IN ANY COUNTRY.  Full Article

Presage Announces Collaboration With Celgene To Investigate Novel Agents With Civo Technology
Thursday, 2 May 2019 

May 2 (Reuters) - Celgene Corp ::PRESAGE ANNOUNCES COLLABORATION WITH CELGENE TO INVESTIGATE NOVEL AGENTS WITH CIVO TECHNOLOGY.PRESAGE BIOSCIENCES - RESEARCH AGREEMENT TO SUPPORT PHASE 0 TUMOR MICRODOSING STUDIES.  Full Article

PRESS DIGEST - Wall Street Journal - Aug. 27

Aug 27 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.